Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)

ABSTRACT Oncology clinical trials are increasingly complex in their design, management, and oversight, and clinical trials continue as the cornerstone to transform cancer care for patients. These multifaceted trials require significant partnership from the institution and investigators to provide support and effort as well as multifaceted teams to conduct and execute these trials seamlessly and effectively. Furthermore, the dissemination of clinical trial findings in a timely and efficient manner requires the continued support from the clinical trials teams, biostatisticians, and co-investigators in terms of time and effort. Dr. Jabbour is a seasoned research specialist, physician scientist, and clinician scientist having a proven track record of diligence and innovation as well as purpose to design, carry out, and complete clinical trials. Her long-standing commitment to clinical trials is paramount as she is a leader at the Rutgers Cancer Institute of New Jersey in mentoring and supporting other clinical trialists, having overseen the Human Research Oversight Committee (HROC/DSMB) and currently overseeing the Scientific Review Board, and she plays integral role in the oversight of clinical trials through a variety of committees both at Rutgers Cancer Institute and nationally. At the national level, Dr. Jabbour is the contact PI for the Rutgers Cancer Institute ETCTN/CTEP grant funding, is a long-standing Co-Chair for the NCI Radiation Research Program Gastrointestinal Interest Group, and is actively involved in a variety of NCI Cooperative Group Committees and Protocols including the ECOG-ACRIN and NRG Oncology Cooperative Groups. Dr. Jabbour is a continued leader and pioneer as a clinician scientist and actively studies the use of novel agents in combination with radiation in ground-breaking clinical trials. Dr. Jabbour will continue her exemplary efforts and work under the auspices of this R50 Mechanism and will continue to revolutionize the care for oncology patients through her state-of-the-art concepts and collaborations through the NCI national cooperative groups.